Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Published: February 2009

Open Access Gateway

Management of Enteropathy-Associated T-Cell Lymphoma: An Algorithmic Approach

Babel N.a · Paragi P.a · Chamberlain R.S.a, b

Author affiliations

aDepartment of Surgery, Saint Barnabas Medical Center, Livingston, N.J., and bDepartment of Surgery, University of Medicine and Dentistry of New Jersey, Newark, N.J., USA

Corresponding Author

Ronald Scott Chamberlain, MD, MPA, FACS

Department of Surgery, Saint Barnabas Medical Center94 Old Short Hills Road

Livingston, NJ 07039 (USA)

Tel. +1 973 322 5195, Fax +1 973 322 2471, E-Mail rchamberlain@sbhcs.com

Related Articles for ""

Case Rep Oncol 2009;2:36–43

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Perforation of the small intestine is the most lethal complication following induction chemotherapy for enteropathy-associated T-cell lymphoma (EATL). We report a case of EATL with a near perforated jejunal ulcer, and suggest a novel approach towards its management. Surgical resection followed by aggressive chemotherapy should limit chemotherapy-associated gastrointestinal toxicity, thus allowing patients to receive adequate dose and duration of chemotherapy. The presented case highlights potential benefits of surgical intervention prior to chemotherapy for EATL.

© 2009 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Published: February 2009

Published online: February 28, 2009
Issue release date: January – April

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 0

eISSN: 1662-6575 (Online)

For additional information: http://www.karger.com/CRO

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.